A brief clinical update on hepatitis C—The essentials

Wisconsin Medical Journal

Volumn 114, Issue 6, 2015, Pages 263-269

  Lee, Jonas ^a   Conniff, James ^a   Kraus, Connie ^b   Schrager, Sarina ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CREATININE; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HEPATITIS C ANTIBODY; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; THYROTROPIN; VIRUS RNA; ANTIVIRUS AGENT;

BLOOD CELL COUNT; CRYOGLOBULINEMIA; ENZYME IMMUNOASSAY; FIBROSIS; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEPATITIS C; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; META ANALYSIS (TOPIC); POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); VIRUS LOAD; VIRUS TRANSMISSION; LIVER TRANSPLANTATION; PRACTICE GUIDELINE; UNITED STATES;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; UNITED STATES; WISCONSIN;

EID: 84950247151     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Huffman MM, Mounsey AL. Hepatitis C for primary care physicians. J Am Board Fam Med. 2014; 27(2):284-291.
2. Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician. 2010; 81(11):1351-1357.
3. Wisconsin Department of Health Services. Division of Public Health. Epidemiologic profile of hepatitis C virus (HCV) in Wisconsin 2014. https://www.dhs.wisconsin.gov/viral-hepatitis/hcv.htm. Revised October 13, 2015. Accessed November 12, 2013.
4. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013; 56(1):40-50.
5. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014; 58(1):40-49.
6. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 159(5):349-357.
7. American Association for the Study of Liver Diseases and Infectious Disease Society of America. Recommendations for Testing, Managing and Treating Hepatitis C. http://www.hcvguidelines.org. Accessed November 12, 2015.
8. Chou R, Clark E, Helfand M. US. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Hepatitis C Virus Infection. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
9. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157(11):817-822.
10. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013; 62(18):362-365.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-1374.
12. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. AHRQ Comparative Effectiveness Reviews. Screening for Hepatitis C Virus Infection in Adults. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
13. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006; 43(2 Suppl 1):S113-120.
14. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014; 61(1 Suppl):S58-68.
15. Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014; 59(1):109-120.
16. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002; 36(6):1439-1445.
17. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008; 49(5):831-844.
18. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010; 8(12):1017-1029.
19. Caviglia GP, Sciacca C, Abate ML, et al. Chronic hepatitis C virus infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin lymphoma. J Gastroenterol Hepatol. 2015; 30(4):742-747.
20. Razavi H, Elkoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57(6):2164-2170.
21. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999; 29(4):1215-1219.
22. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S47-56.
23. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int. 2011; 31 Suppl 1:18-22.
24. Hill A, Simmons B, Saleem J, Cooke G. Five–year risk of late relapse or reinfection with hepatitis C after sustained virological response: meta-analysis of 49 studies in 8534 patients. Presented at the Conference on Retroviruses and Opportunistic Infections; February 2015; Seattle, WA.
25. Birnkrant D. Direct-acting antivirals: a new era for the treatment of chronic hepatitis C. Presented at the Antiviral Drugs Advisory Committee Meeting; April 27-28, 2011; Silver Spring, MD. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM254076.pdf. Accessed November 12, 2015.
26. Childs-Kean LM, Hand EO. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clin Ther. 2015;37(2):243-267.
27. FDA approves new treatment for hepatitis C virus [news release]. Silver Spring, MD: US Food and Drug Administration; November 22, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm. Accessed November 12, 2015.
28. FDA approves Solvadi for chronic hepatitis C [news release]. Silver Spring, MD: US Food and Drug Administration; December 6, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm. Accessed November 12, 2015.
29. FDA approves first combination pill to treat hepatitis C [news release]. Silver Spring, MD: US Food and Drug Administration; October 10, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm. Accessed November 12, 2015.
30. FDA approves Viekira Pak to treat hepatitis C [news release]. Silver Spring, MD: US Food and Drug Administration; December 19, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm. Accessed November 12, 2015.
31. Smith MA, Chan J, Mohammad RA. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Ann Pharmacother. 2015;49(3):343-350.
32. Gane E, Kershenobich D, Seguin-Devaux C, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden—volume 2. J Viral Hepat. 2015;22 Suppl 1:46-73.
33. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11(3):333-341.
34. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection [published online ahead of print February 13, 2015]. Ann Pharmacother. doi:10.1177/1060028015570729.